%A Xie,Jianfeng %A Jin,Chunchun %A Liu,Mengmeng %A Sun,Kun %A Jin,Zhanqiang %A Ding,Zhimin %A Gong,Xuehao %D 2022 %J Frontiers in Oncology %C %F %G English %K Magnetic Resonance Imaging,Transrectal ultrasound,prostate cancer,Targeted biopsy,Meta-analysis %Q %R 10.3389/fonc.2022.880336 %W %L %M %P %7 %8 2022-May-23 %9 Systematic Review %+ Zhimin Ding,Department of Ultrasound, First Affiliated Hospital of Southern University of Science and Technology, Second Clinical College of Jinan University, Shenzhen Medical Ultrasound Engineering Center, Shenzhen People’s Hospital,China,jimding03@126.com %+ Xuehao Gong,Department of Ultrasound, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital,China,jimding03@126.com %# %! Targeted Biopsy and Systematic Biopsy for Diagnosis of Prostate Cancer %* %< %T MRI/Transrectal Ultrasound Fusion-Guided Targeted Biopsy and Transrectal Ultrasound-Guided Systematic Biopsy for Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis %U https://www.frontiersin.org/articles/10.3389/fonc.2022.880336 %V 12 %0 JOURNAL ARTICLE %@ 2234-943X %X PurposeFor men suspected of having prostate cancer (PCa), the transrectal ultrasound (TRUS)-guided systematic biopsy (SB) was performed. MRI/TRUS fusion guided-targeted biopsy (MRI-TB) could enhance PCa detection, allowing sampling of sites at higher risk which were not obvious with TRUS alone. The aim of this systematic review and meta-analysis was to compare the detection rates of prostate cancer by MRI-TB or MRI-TB plus SB versus SB, mainly for diagnosis of high-risk PCa.MethodsA literature Search was performed on PubMed, Cochrane Library, and Embase databases. We searched from inception of the databases up to January 2021.ResultsA total of 5831 patients from 26 studies were included in the present meta-analysis. Compared to traditional TRUS-guided biopsy, MRI-TB had a significantly higher detection rate of clinically significant PCa (RR=1.27; 95%CI 1.15-1.40; p<0.001) and high-risk PCa (RR=1.41; 95% CI 1.22-1.64; p<0.001), while the detection rate of clinically insignificant PCa was lower (RR=0.65; 95%CI 0.55-0.77; p<0.001). MRI-TB and SB did not significantly differ in the detection of overall prostate cancer (RR=1.04; 95%CI 0.95-1.12; p=0.41). Compared with SB alone, we found that MRI-TB plus SB diagnosed more cases of overall, clinically significant and high-risk PCa (p<0.001).ConclusionCompared with systematic protocols, MRI-TB detects more clinically significant and high-risk PCa cases, and fewer clinically insignificant PCa cases. MRI-TB combined with SB enhances PCa detection in contrast with either alone but did not reduce the diagnosis rate of clinically insignificant PCa.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/#searchadvanced, CRD42021218475.